Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorFINGER, R. P.
dc.contributor.authorDAIEN, V.
dc.contributor.authorTALKS, J. S.
dc.contributor.authorMITCHELL, P.
dc.contributor.authorWONG, T. Y.
dc.contributor.authorSAKAMOTO, T.
dc.contributor.authorELDEM, B. M.
dc.contributor.authorLÖVESTAM-ADRIAN, M.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535
IDREF: 028739272
dc.date.accessioned2021-03-09T14:18:08Z
dc.date.available2021-03-09T14:18:08Z
dc.date.issued2020-12-28
dc.identifier.issn1755-3768en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26466
dc.description.abstractEnDespite the growing importance of real-world evidence (RWE) for guiding clinical decisions in retinal disease, there is currently no widely used guidance available for assessing the quality and relevance of RWE studies in ophthalmology. This paper summarizes the development of a user-friendly tool that facilitates assessment of the quality of available RWE for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). A literature search was conducted to identify tools developed to assess the quality of RWE, in order to identify the most appropriate framework on which to base this tool. The Good Research for Comparative Effectiveness (GRACE) guidelines was chosen for this purpose as it is designed to assess the quality of observational studies and has been extensively validated, including demonstration of strong sensitivity and specificity. The GRACE guidelines were adapted to develop a straightforward tabular tool that allows simple assessment and comparison of the quality of published evidence in retinal disease for researchers and physicians alike, and includes guidance on treatment details, outcome measures, study population, and controlling for bias. The newly developed tool provides a simple method to support assessment of the strength of evidence and certainty of conclusions drawn from RWE in retinal disease, to ensure clinical decision-making is influenced by the highest quality evidence.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.title.enA novel tool to assess the quality of RWE to guide the management of retinal disease
dc.title.alternativeActa Ophthalmolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/aos.14698en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33369881en_US
bordeaux.journalActa Ophtalmologicaen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03163915
hal.version1
hal.date.transferred2021-03-09T14:18:12Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Acta%20Ophtalmologica&rft.date=2020-12-28&rft.eissn=1755-3768&rft.issn=1755-3768&rft.au=FINGER,%20R.%20P.&DAIEN,%20V.&TALKS,%20J.%20S.&MITCHELL,%20P.&WONG,%20T.%20Y.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée